Summary of HR 4396 - Uterine Cancer Study Act of 2025

Purpose and Intent

The Uterine Cancer Study Act of 2025 (HR 4396) aims to enhance the understanding of uterine cancer through comprehensive research. The bill seeks to address the growing concerns surrounding uterine cancer, which has seen an increase in incidence and mortality rates in recent years. By funding targeted studies, the legislation intends to improve prevention, diagnosis, and treatment options for this type of cancer.

Key Provisions

• Research Funding: The bill proposes the allocation of federal funds to support research initiatives focused on uterine cancer. This includes studies on risk factors, genetic predispositions, and effective treatment methodologies.

• Collaboration with Institutions: HR 4396 encourages partnerships between federal health agencies, academic institutions, and cancer research organizations to foster a multidisciplinary approach to uterine cancer research.

• Data Collection and Analysis: The legislation mandates the collection of comprehensive data on uterine cancer cases, which will be used to identify trends and inform future research directions.

• Public Awareness Campaigns: The bill includes provisions for public health campaigns aimed at raising awareness about uterine cancer symptoms, risk factors, and the importance of early detection.

Affected Parties

• Patients and Survivors: Individuals diagnosed with uterine cancer and their families will benefit from improved research outcomes, leading to better treatment options and support services.

• Healthcare Providers: Medical professionals will gain access to new research findings that can enhance their understanding and management of uterine cancer.

• Research Institutions: Academic and research organizations will receive funding and support to conduct studies, potentially leading to breakthroughs in uterine cancer treatment and prevention.

Procedural Aspects

• Introduced Date: The bill was introduced in the House on July 15, 2025.

• Committee Referral: Following its introduction, HR 4396 was referred to the House Committee on Energy and Commerce for further consideration.

• Related Legislation: HR 4396 has a companion bill, S 2285, which is being considered in the Senate, indicating bipartisan interest in addressing uterine cancer research.

Conclusion

The Uterine Cancer Study Act of 2025 represents a significant legislative effort to combat uterine cancer through dedicated research and public awareness. By facilitating collaboration among various stakeholders and funding critical studies, the bill aims to improve outcomes for those affected by this disease. As it progresses through the legislative process, stakeholders will be watching closely for developments and potential impacts on cancer research funding and public health initiatives.